Home Apoptosis TNF-alpha inhibitor N-Acetylcysteine (NAC chemical, N-Acetyl-L-Cysteine)

연구용

N-Acetylcysteine (NAC chemical, N-Acetyl-L-Cysteine) ROS inhibitor

제품 번호: S1623

Acetylcysteine (N-acetyl-l-cysteine, NAC,N-acetylcysteine) is a ROS(reactive oxygen species) inhibitor that antagonizes the activity of proteasome inhibitors. It is also a tumor necrosis factor production inhibitor. Acetylcysteine(N-acetyl-l-cysteine) suppresses TNF-induced NF-κB activation through inhibition of IκB kinases. Acetylcysteine(N-acetyl-l-cysteine) induces apoptosis via the mitochondria-dependent pathway. Acetylcysteine(N-acetyl-l-cysteine) inhibits ferroptosis and virus replication.Solutions are unstable and should be fresh-prepared.
N-Acetylcysteine (NAC chemical, N-Acetyl-L-Cysteine) TNF-alpha inhibitor Chemical Structure

화학 구조

분자량: 163.19

바로가기

품질 관리 (Quality Control)

배치: 순도: 99.95%
99.95

세포 배양, 처리 및 작업 농도
(Cell Culture, Treatment & Working Concentration)

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
HUVEC cells Function assay 10μM 2h HUVECs were pretreated with 10 μM NAC for 2 hours, and then treated with 0.5 μM PCB 118. presentce of NAC for 48 hours. 28592194
HUVEC cells Function assay 2μM,4μM,8μM 90min HUVECs that were exposed with serum of P. falciparum and treated with NAC 2 µM，4 µM，8 µM. Supernatant from culture and lysed cells culture were measured for H2O2, GSH and MDA levels. 21602763
BL21 (DE3) Function assay 30 mins Inhibition of hexahistidine-tagged IMP-7 (unknown origin) expressed in Escherichia coli BL21 (DE3) cells using fluorocillin as substrate incubated for 30 mins by TECAN fluorescent plate reader analysis, IC50 = 20.7 μM. 25815530
PC12 Cytotoxicity assay 24 hrs Inhibition of 6-hydroxydopamine induced cytotoxicity in rat PC12 cells pretreated for 24 hrs assessed as elevation of intracellular glutathione level 17158454
PC12 Cytotoxicity assay 24 hrs Inhibition of hydrogen peroxide induced cytotoxicity in rat PC12 cells pretreated for 24 hrs assessed as elevation of intracellular glutathione level 17158454
NHBE Cytotoxicity assay 1 mM 18 hrs Cytoprotective activity in NHBE cells assessed as inhibition of tBHP-induced GSH depletion at 1 mM preincubated for 18 hrs followed by tBHP addition for 4 hrs by thiostar dye based fluorescence assay 27031670
HUVEC Antioxidant assay 5 mmol/L 4 hrs Antioxidant activity against H2O2-induced lipid accumulation in HUVEC cells assessed as reduction in MDA level at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs 22841280
HUVEC Antioxidant assay 5 mmol/L 4 hrs Antioxidant activity in HUVEC cells assessed as reduction in H2O2-induced GSH activity at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs 22841280
HUVEC Cytotoxicity assay 5 mmol/L 4 hrs Inhibition of H2O2-induced cytotoxicity in HUVEC cells assessed as cell viability at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs by MTT assay 22841280
HUVEC Cytotoxicity assay 5 mmol/L 4 hrs Inhibition of H2O2-induced cytotoxicity in HUVEC cells assessed as LDH release at 5 mmol/L incubated 4 hrs prior to H2O2 challenge measured after 12 hrs by LDH assay 22841280
SH-SY5Y Neuroprotective assay 5 mM 4 hrs Neuroprotective activity in H2O2-stimulated human SH-SY5Y cells assessed as upregulation of Bax expression at 5 mM incubated for 4 hrs prior to H2O2 challenge measured after 12 hrs by Western blotting analysis 23403085
SH-SY5Y Neuroprotective assay 5 mM 4 hrs Neuroprotective activity in H2O2-stimulated human SH-SY5Y cells assessed as downregulation of Bcl2 expression at 5 mM incubated for 4 hrs prior to H2O2 challenge measured after 12 hrs by Western blotting analysis 23403085
HT22 Neuroprotective assay 5 mM 24 hrs Neuroprotective activity against glutamate-induced cell death in mouse HT22 cells assessed as increase in cell viability at 5 mM after 24 hrs by MTT assay 29122481
HT22 Neuroprotective assay 50 uM 10 to 12 hrs Neuroprotective activity against glutamate-induced cell death in mouse HT22 cells assessed as reduction in apoptotic cells at 50 uM after 10 to 12 hrs by Annexin V-alexa 488/propidium iodide staining based flow cytometry 29122481
HL-7702 Hepatoprotective assay 10 uM 24 hrs Hepatoprotective activity against APAP-induced cell injury in human HL-7702 cells assessed as increase in survival rate at 10 uM pre-incubated for 24 hrs before APAP addition and measured 6 hrs post APAP challenge by MTT assay 28729056
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성 (Chemical Information, Storage & Stability)

분자량 163.19 화학식

C5H9NO3S

 보관 (수령일로부터) 3 years -20°C powder
CAS 번호 616-91-1 SDF 다운로드 원액 보관 용액은 불안정합니다. 신선하게 준비하거나 소량의 사전 포장된 크기를 구매하십시오. 수령 즉시 재포장하십시오.
동의어 N-acetylcysteine Smiles CC(=O)NC(CS)C(=O)O

용해도 (Solubility)

In vitro
배치:

DMSO : 33 mg/mL (202.21 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Water : 33 mg/mL

Ethanol : 33 mg/mL

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘 (Mechanism of Action)

Targets/IC50/Ki
NF-κB
Ferroptosis
ROS
TNF-α
시험관 내(In vitro)

Acetylcysteine (N-Acetylcysteine, NAC) inhibits activation of c-Jun N-terminal kinase, p38 MAP kinase and redox-sensitive activating protein-1 and nuclear factor kappa B transcription factor activities regulating expression of numerous genes. It can also prevent apoptosis and promote cell survival by activating extracellular signal-regulated kinase pathway, a concept useful for treating certain degenerative diseases. This compound directly modifies the activity of several proteins by its reducing activity.

It prevents apoptotic DNA fragmentation and maintains long-term survival in the absence of other trophic support in serum-deprived PC12 cells. It also prevents death of PC12 cells and sympathetic neurons.

It causes dose-dependent reductions in viability in rat and human aortic smooth muscle cells.

It activates the Ras-extracellular signal-regulated kinase (ERK) pathway in PC12 cells. This compound protects neuronal cells from death evoked by withdrawal of trophic support. It increases nitric oxide (NO) release from protein-bound stores in vascular tissue. Its pretreatment of PC12 cells interferes with NGF-dependent signaling and neurite outgrowth, and it was suggested that NAC interferes with redox-sensitive steps in the NGF mechanism.

생체 내(In vivo)

In both the T-maze footshock avoidance paradigm and the lever press appetitive task, N-acetylcysteine (NAC) improves cognition of 12-month-old SAMP8 mice without inducing non-specific effects on motor activity, motivation to avoid shock, or body weight.

참조
  • [4] https://pubmed.ncbi.nlm.nih.gov/9592085/
  • [5] https://pubmed.ncbi.nlm.nih.gov/12603840/
  • [6] https://pubmed.ncbi.nlm.nih.gov/23772801/
  • [7] https://pubmed.ncbi.nlm.nih.gov/1544168/
  • [8] https://pubmed.ncbi.nlm.nih.gov/29426002/
  • [9] https://pubmed.ncbi.nlm.nih.gov/30294906/
  • [10] https://pubmed.ncbi.nlm.nih.gov/35023619/

임상시험 정보 (Clinical Trial Information)

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT04520139 Not yet recruiting
Ovarian Cancer|Cognitive Impairment
University of California Irvine|Jarrow Formulas Inc
 December 2024 Phase 1|Phase 2
NCT06112834 Not yet recruiting
Botulism
California Department of Public Health
 June 2024 Phase 2
NCT06260566 Not yet recruiting
Biliary Atresia
Sanjiv Harpavat|Baylor College of Medicine
 May 2024 Phase 1
NCT06377410 Not yet recruiting
Chronic Obstructive Pulmonary Disease
National University of Malaysia
 May 1 2024 Not Applicable
NCT06223568 Not yet recruiting
Squamous Cell Carcinoma of the Head and Neck|Oropharynx|Human Papillomavirus Viruses|Drug Therapy|Cancer Vaccine
National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)
 May 15 2024 Phase 2